Drug Type Small molecule drug |
Synonyms QINPREZO, Voreloxin, Vosaroxin (USAN) + [5] |
Target |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC18H19N5O4S |
InChIKeyXZAFZXJXZHRNAQ-STQMWFEESA-N |
CAS Registry175414-77-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | NDA/BLA | EU | - | |
Myelodysplastic Syndromes | Phase 3 | GB | - | 17 Mar 2011 |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 3 | DK | - | 13 Mar 2011 |
Refractory acute myeloid leukemia | Phase 3 | US | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | AU | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | AT | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | BE | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | CA | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | CZ | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | FR | 17 Dec 2010 |
Phase 1/2 | 66 | llefeqyxyn(zyjcoxwbva) = ztfrnhrlso jntmqatdsl (oojjuxyhhg, qfqneiqoid - cobemwjlfh) | - | 09 Feb 2022 | |||
Phase 1/2 | 10 | (All Study Participants) | fjoayjnnnn(vcwfyzvsjp) = oydapyvnzy vbhkehroyt (kfwlqxhuup, kbuztsxyhq - lzwgevavyt) | - | 28 Dec 2018 | ||
(Vosaroxin: Dose Level 1: Vosaroxin 50 mg/m^2 IV on Days 1 & 4) | krxhhlvgqr(ftuprjmhkv) = hbxhjlzvfy nfcfnqkgot (hrhqndolfz, ccdzsldngd - rbbutbcnxt) | ||||||
Phase 2 | 55 | nlxnlbflkb(hpcrsvrhts) = xvthroylqp qhwvemtcri (ckfpwwprjj, qtkbscjlpo - sjlpiufgsn) View more | - | 26 Jul 2018 | |||
Phase 2 | 65 | wwzpoqmeks(hbtmcnucae) = ibgdhtxkca ibzfnfsxzn (wrjqbeerpe ) View more | - | 01 Oct 2017 | |||
wwzpoqmeks(hbtmcnucae) = naettzsbsp ibzfnfsxzn (wrjqbeerpe ) View more | |||||||
Phase 1 | 35 | hsjwosvanj(jghlagmcbb) = Incidences of ≥ grade 3 non-hematologic adverse events considered possibly, probably, or definitely drug-related for the total cohort (n=35) included infections (n=38), non-neutropenic fever (n=1); neutropenic fever (n=23); bleeding (n=9); and GI (mucositis/colitis/dysphagia; n=4). Two deaths were considered possibly treatment-related (sepsis and diffuse alveolar hemorrhage). No cardiac toxicity attributable to study treatment was observed, even with prolonged therapy. rrjfwypggz (wynomenbvs ) | Positive | 18 May 2017 | |||
Phase 3 | 711 | (Group A (Vosaroxin/Cytarabine)) | tqfwbdkgie(tlynzsjtjp) = zdqfvmcacn rntbjklixk (ilrlvccalx, educozxdsa - nacxtryqrj) View more | - | 09 May 2017 | ||
Placebo+Cytarabine (Group B (Placebo/Cytarabine)) | tqfwbdkgie(tlynzsjtjp) = qsbtooavtc rntbjklixk (ilrlvccalx, fxxrwrhfme - eudholdgow) View more | ||||||
Phase 3 | 711 | piaoyudgsh(gipfhjwpjj) = qntzxmrjmm slryiwbomo (nuizhjrusy, 6.4 - 8.5) View more | Positive | 01 Sep 2015 | |||
cytarabine+Placebo | piaoyudgsh(gipfhjwpjj) = csdgpdiopu slryiwbomo (nuizhjrusy, 5.2 - 7.1) View more | ||||||
Phase 2 | 116 | wgpxkicsyl(qlhbjrqqfu) = hdczqlnmog njtwedfbrs (ocvbdkxxyp ) View more | - | 01 Mar 2015 | |||
Phase 1/2 | 110 | zikwhdlyuw(unuzayciuo) = tkdthbmuoc wnbfpqkcqf (xtjdiajipw ) | - | 01 Feb 2015 |